Cannabis
CBD Oil Market Size 2020-Industry Share, Growth, Trends, Revenue Analysis, Top Leaders-Dr. Hemp Me, Green Roads, Royal CBD, CBD Oil Europe, King CBD: Says DBMR Analyst
NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) — Data Bridge Market Research recently released Global CBD Oil Market research with more than 220 market data tables and figures and an easy to understand TOC in “Global CBD Oil Market research”, so you can get a variety of ways to maximize your profits. CBD Oil Market predicted until 2027. The main targets of the company for this study are Dr. Hemp Me., QC Infusion, Hemp Production Services, Hudson Valley Hemp, LLC, Green Roads, Royal CBD, Moon Mother Hemp Company, CBD Oil Europe, King CBD, FOLIUM BIOSCIENCES, CV Sciences, Botanicals, LLC and among others.
The CBD Oil Market (COVID-19 Impact Analysis) 2020 Industry Report makes available an exhaustive overview of product specification, technology, product type and production analysis considering major factors such as revenue, costing, and gross margin. This market report also studies the market status, market share, size, growth rate, demand, revenue, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, and distributors with the Porter’s Five Forces analysis. Thus, the transparent, trustworthy and extensive market information and data included in this report will definitely help develop business and improve return on investment (ROI). The study objectives are to present the CBD Oil development in North America, Europe, China, Japan, Southeast Asia, India, and Central South America.CBD Oil Market is expected to witness growth at a rate of 31.90% for the forecast period of 2020 to 2027. CBD Oil Market Report analyses the growth, which is currently being owed to the focus of unconventional application of hemp extract and CBD oil for medical purposes.Get Sample Report: To Know the Impact of COVID-19 on this Industry @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cbd-oil-market LIFE SCIENCE COMPANIES CHALLENGED BY CHANGING MARKET DYNAMICS DURING COVID-19Data Bridge Market Research is helping Medtech and Biopharma companies find a footing by changing market access strategies and analysing the new revenue pockets. The competitive landscape has changed drastically within recent weeks.CBD Oil Market is growing owing to certain reasons likely increasing frequency of psychical dysfunctions, inflation in assent of hemp oil-infused commodities, progressing legalization in the farming of industrialized hemp, expanding utilization in individual care, and food & refreshments commodities, and progressing amount of chronic disorders. Some of the circumstances may act as the restraint for the market such as complicated administrative formation for the acceptance of industrialized hemp and the dearth of procurement of seeds for the agriculture use of hemp. To overcome certain hindrances innovative merchandise improvements from industrialized hemp will act as the opportunity for the market.Speak To Our Analyst: Impact of COVID-19 on this Market @ https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-cbd-oil-marketNorth America is anticipated to behold the most substantial percentage of CBD oil market due to the constituents such as legalization of cannabis in many nations of the U.S. and the mounting knowledge regarding the advantages of CBD oil.Global CBD Oil Market research report also provides the latest manufacturing data and industry future trends, allowing you to identify the products and end users driving profits growth and productivity. The Market report lists the most important competitors and provides the insights strategic industry Analysis of the key factors influencing the market. The report includes the forecasts, investigation and discussion of significant industry trends, market volume, market share estimates and profiles of the leading industry Players. Global CBD Oil Industry Market Research Report is providing exclusive vital statistics, information, data, trends and competitive landscape details.The Segments and Sub-Section of CBD Oil Market are shown below:By Source (Organic and Conventional)By Product Type (Marijuana Based, Hemp Based)By Application (Multiple Sclerosis, Depression and Sleep Disorders, Neurological Pain, Others)To Gain More Insights into the CBD Oil Market Analysis, Browse Summary of the Research Report@ https://www.databridgemarketresearch.com/reports/global-cbd-oil-marketCOMPANIES MENTIONED INCLUDE (we can also add the other companies as you want.):Hemp MeQC Infusion Hemp Production ServicesHudson Valley Hemp LLC.Green RoadsRoyal CBDMoon Mother Hemp CompanyCBD Oil EuropeKing CBDFOLIUM BIOSCIENCESCV Sciences, IncPharmahemp d.o.oGaia Botanicals, LLCCanazilKazmiraSpring Creek LabsCavendish Nutrition Fulfillment LLCIsodiol International IncHempLife TodayHemp Oil Canada IncComplete Report Details with Table of Content and Figures@ https://www.databridgemarketresearch.com/toc/?dbmr=global-cbd-oil-marketNo. of CBD Oil Market Report Pages: 350No of Tables: 220No of Figures: 60Scope of Report: The Market report lists the most important competitors and provides the insights strategic industry Analysis of the key factors influencing the market. This report will help you to establish a landscape of industrial development and characteristics of the CBD Oil market. The Global CBD Oil market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, price, cost, revenue and gross margins.Important years considered in the study are:Historical year – 2010-2018; Base year – 2019; Forecast period– 2020 to 2027 [** unless otherwise stated]The countries covered in the CBD Oil Market Report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.For More Information or Query or Customization Before Buying, Visit @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cbd-oil-marketGlobal CBD Oil Market Scope and Market SizeCBD oil market is segmented on the basis of source, product type and application. The growth amongst the different segments helps you in attaining the knowledge related to the different growth factors expected to be prevalent throughout the market and formulate different strategies to help identify core application areas and the difference in your target markets.On the basis of source, the CBD oil market is segmented into organic and conventional.On the basis of product type, the CBD oil market is segmented into marijuana based, and hemp based.On the basis of application, the CBD oil market is segmented into multiple sclerosis, depression and sleep disorders, neurological pain, and others.The report also focuses on global major leading industry players of Global CBD Oil Market providing information such as company profiles, product picture and specification, price, capacity, cost, production, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.Buy the Latest Detailed with 30% Discount on this Report @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-cbd-oil-marketThe Global CBD Oil market development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered. With tables and figures helping analyze worldwide Global CBD Oil market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.Some of the Major Highlights of TOC covers:Chapter 1: Methodology & ScopeDefinition and forecast parametersMethodology and forecast parametersData SourcesChapter 2: Executive SummaryBusiness trendsRegional trendsProduct trendsEnd-use trendsChapter 3: CBD Oil Industry InsightsIndustry segmentationIndustry landscapeVendor matrixTechnological and innovation landscapeChapter 4: CBD Oil Market, By RegionChapter 5: Company ProfileBusiness OverviewFinancial DataProduct LandscapeStrategic OutlookSWOT AnalysisThanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.Trending Related Reports:Global CBD Oil Extract Market By Source Type (Hemp, Marijuana), Distribution Channel (B2B, B2C), End Use (Medical, Personal use, Pharmaceutical, Wellness), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027. https://www.databridgemarketresearch.com/reports/global-cbd-oil-extract-marketGlobal CBD Edibles Market, By Source Type (Hemp, Marijuana), Application (Personal Care & Cosmetics, Pharmaceutical, Food & Beverage, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027. https://www.databridgemarketresearch.com/reports/global-cbd-edibles-marketGlobal CBD Infused Edible Market, By Source (Hemp, Marijuana), Form (Process Oil, Distillate, Isolate), Grade (Food, Therapeutic), Application (Food & Beverage, Cosmetic & Personal Care, Pharmaceutical, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027 https://www.databridgemarketresearch.com/reports/global-cbd-infused-edible-marketGlobal Cannabis Infused Products Market, By Product (Skincare, Cosmetics, Haircare, Intimate Lubricants, Pharmaceuticals, Gummies, Pills, Infused Beverages, and Other), Source (Hemp, Marijuana), Distribution Channel (B2B, B2C), End User (Medical, Personal Use, Pharmaceuticals, Wellness), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends & Forecast to 2027 https://www.databridgemarketresearch.com/reports/global-cannabis-infused-products-marketGlobal Medical Cannabis Market,By Species (Cannabis Indica, Sativa, Hybrid), Derivatives (Cannabidiol (CBD), Tetrahydrocannabinol (THC), Others), Application (Pharmaceutical Industry, Research and Development Centers, Others), Route of Administration (Oral Solutions and Capsules, Smoking, Vaporizers, Topicals, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027. https://www.databridgemarketresearch.com/reports/global-medical-cannabis-marketAbout Data Bridge Market Research:An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience, which was formulated and framed in the year 2015 in Pune.Contact:Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
[email protected]
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company’s board of directors (the “Board“) effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company’s commitment to driving growth while focusing on sustainable profitability.
“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”
Mr. Arbel retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.
“I am honored to join the Board of Directors at IMCC,” said Mr. Arbel. “I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”
Arbel holds a BA and MBA from Tel Aviv University.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the stated benefits Mr. Arbel’s appointment, including the further strengthening the Company’s commitment to driving growth in the German market while focusing on sustainable profitability; and Mr. Arbel’s international experience and track record in banking and finance will be invaluable to the Company.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance becoming invaluable to the Company.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance not becoming valuable to the Company.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
[email protected]
Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-302244961.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
-
Indivior1 week agoIndivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
-
Cannabis3 days ago
One World Products Issues Shareholder Update Letter
-
Cannabis3 days agoIM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors
